Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Four Out Of 106 Heart Replacement Valves From Pig Hearts Failed
Pig heart valves used to replace defective aortic valves in human patients failed much earlier and more often than expected, says a report from cardiac surgeons at Washington University School of Medicine in St. Louis. This is the first report to demonstrate this potential problem, the researchers say.
generic viagra online
Culturally Appropriate Nutritional Intervention Needed, According To Nutrition Experts
The prevalence of overweight in the US population is among the highest in Mexican-American children and adolescents. In a study of 1,030 Hispanic children between the ages of 4 and 19, published in the June 2009 issue of the Journal of the American Dietetic Association, researchers from the Baylor College of Medicine found less than optimal diets in both overweight and non-overweight participants. Drugshop to buy zoloft online and other pills.
News of the day
Study Demonstrating Lurasidone Is Effective In Patients With Schizophrenia Published In The Journal Of Clinical Psychiatry
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical Psychiatry. This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy assessments at all study visits starting at day 3. In addition, lurasidone was generally well-tolerated and was associated with weight and metabolic changes that were similar to placebo.
Public Health

OncoGenex Pharmaceuticals To Webcast ASCO Reception On May 30, 2009

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, May 30, 2009. The webcast will begin at 7:10 p.m. EDT. During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of a randomized Phase 2 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer. Guest speakers include: - Dr. Kim Chi, OGX-011 Principal Investigator, BC Cancer Agency - Dr. Oliver Sartor, Medical Oncologist, Tulane Medical School - Dr. Tomasz Beer, Medical Oncologist, Oregon Health & Science University - Dr. Brent Blumenstein, Independent Statistician, Trial Architecture Consulting - Dr. Martin Gleave, Distinguished Professor, Department of Urologic Sciences, University of British Columbia and Chief Scientific Officer, OncoGenex Pharmaceuticals, Inc. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at http://www.oncogenex.com. OncoGenex Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009